Eagle Pharmaceuticals' Q1 Adjusted Earnings, Revenue Decline; Files 'Treakisym' Formulation With Japanese Regulator
08:24 AM EDT, 05/10/2021 (MT Newswires) -- Eagle Pharmaceuticals (EGRX) reported Q1 adjusted earnings Monday of $0.24 per diluted share, compared with $0.84 a year earlier. Analysts polled by Capital IQ expected $0.73.
Revenue for the biotech company for the quarter ended March 31 was $41.2 million, compared with $46 million a year earlier. Analysts polled by Capital IQ expected revenue of $45 million.
The company also reported its Treakisym liquid formulation has been filed with Japan's Pharmaceuticals and Medical Devices Agency.
Eagle licensed to SymBio Pharmaceuticals intellectual property to develop, market and sell ready-to-dilute and rapid infusion formulations of bendamustine under the trade name Treakisym in Japan using Eagle's proprietary technology. As part of the deal, SymBio assumed responsibility for regulatory approval of the Treakisym RTD and RI products using the licensed technology in Japan.
Price: 41.65, Change: 0.00, Percent Change: 0.00